MNTF Peptides for Neuronal Viability and Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuronal disorders lack effective solutions for enhancing neuronal cell viability and proliferation, particularly in neurodegenerative and neuromuscular diseases affecting the central and peripheral nervous systems.
Innovation Solution
Development of novel synthetic and purified MNTF peptides or analogs, including specific sequences and modifications such as N-terminal conjugation with penetration enhancers, to modulate neuronal cell viability and growth, promoting neurotrophic effects and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neuronal disorders, then current treatment protocols are maintained, but neuronal cell viability and proliferation are not effectively enhanced
Solution Approach 1:
The patent creates synthetic copies of MNTF peptides that replicate the natural trophic effects. The synthetic peptides (e.g., SEQ ID NOS: 1-22) are designed to copy the essential amino acid sequences of natural MNTF, particularly containing the conserved FS residues at positions 17 and 18, thereby reproducing the cell survival and growth-promoting effects without requiring extraction from natural sources.
Solution Approach 2:
The patent modifies peptide parameters by creating analogs with specific amino acid substitutions, deletions, or additions while maintaining the core MNTF sequence. These parameter changes allow optimization of peptide stability, activity, and pharmacokinetic properties. For example, the patent describes analogs with conservative substitutions at non-critical positions that enhance peptide half-life or reduce immunogenicity while preserving neurotrophic activity.
2Reliability
If full-length MNTF molecules are used, then neurotrophic effects are achieved, but synthesis complexity and cost increase
Solution Approach 1:
The patent extracts and isolates the essential active components of MNTF - specifically the critical amino acid sequences containing the FS residues at positions 17 and 18. By identifying and utilizing only the minimal necessary sequence elements (such as 2-mer, 3-mer, 4-mer, or 5-mer peptides), the patent reduces manufacturing complexity while maintaining neurotrophic activity.
Solution Approach 2:
The patent segments the full-length MNTF molecule into smaller functional units - specific peptide fragments containing the essential FS residues. These segmented peptides (e.g., SEQ ID NOS: 1-22) can be synthesized more easily and combined or used independently to achieve the desired therapeutic effect, simplifying the manufacturing process compared to producing the complete native protein.
3Ease of manufacture
If peptide penetration barriers are not addressed, then synthesis is simplified, but therapeutic efficacy at target site is reduced
Solution Approach 1:
The patent introduces penetration enhancers as intermediary substances that facilitate peptide delivery across biological barriers. These enhancers act as mediators between the synthetic peptides and the target neuronal cells, enabling efficient uptake and distribution without complicating the core peptide synthesis process. The enhancers temporarily interact with the peptide to promote barrier crossing, then release the active peptide at the target site.
Data Source
AI summary
The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides between two and six amino acids in length are provided, as well as analogs of these MNTF peptides that are modified by covalent attachment to another moiety. Other embodiments are described herein.